Trials / Completed
CompletedNCT02797067
Rectal Indomethacin to Prevent Post ESWL-pancreatitis
Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,370 (actual)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.
Detailed description
It is a prospective, double-blind, randomized controlled trial. Patients with painful chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) who are treated with ESWL at Changhai Hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | indomethacin suppository | 100mg rectal indomethacin 30min before ESWL |
| DRUG | Glycerin Suppository | 30min before ESWL |
Timeline
- Start date
- 2016-05-31
- Primary completion
- 2019-07-01
- Completion
- 2021-08-01
- First posted
- 2016-06-13
- Last updated
- 2022-05-26
- Results posted
- 2022-05-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02797067. Inclusion in this directory is not an endorsement.